Market Access News | pharmaphorum

News

CVS Health funds insomnia app, stop smoking support could fo...

The influential US pharmacy benefit manager CVS Health has said it will fund an insomnia app, allowing it to be paid for in the same way as drugs by insurers and employers.

News

Minister says using generic CF drug is an option in Orkambi ...

Vertex is coming under increased pressure to sign a deal with the NHS covering its Orkambi cystic fibrosis (CF) drug, with a government minister suggesting she would consider implementing l

News

Celgene gets MS blockbuster-in-waiting ozanimod back on trac...

Regulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple sclerosis, setting up verdicts next year.

News

Motif pummelled as FDA asks for more data on antibiotic

Shares in UK biotech Motif Bio fell more than 50% after its much-delayed antibiotic was held up at the FDA once again by a request for another clinical trial.

News

Celgene gets speedy review for thalassaemia drug luspatercep...

It’s shaping up to be a landmark year for the community of patients with rare blood disorder beta thalassaemia.

News

Orkambi parents start ‘buyers club’ to import generic versio...

A group of parents in the UK have taken matters into their own hands in an effort to get their children access to Orkambi, the cystic fibrosis drug at the centre of a three and a half year

CVS Health funds insomnia app, stop smoking support could fo...

Minister says using generic CF drug is an option in Orkambi ...

Celgene gets MS blockbuster-in-waiting ozanimod back on trac...

Motif pummelled as FDA asks for more data on antibiotic

Celgene gets speedy review for thalassaemia drug luspatercep...

Orkambi parents start ‘buyers club’ to import generic versio...

Tarsus places $800m wager on Alkeus' Stargardt therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks